Head to Head Contrast: Candel Therapeutics (NASDAQ:CADL) and Elevation Oncology (NASDAQ:ELEV)
Head to Head Contrast: Candel Therapeutics (NASDAQ:CADL) and Elevation Oncology (NASDAQ:ELEV)
Candel Therapeutics (NASDAQ:CADL – Get Rating) and Elevation Oncology (NASDAQ:ELEV – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.
凱德爾治療公司(納斯達克代碼：CADL-GET評級)和Elevation Oncology(納斯達克代碼：ELEV-GET評級)都是小盤醫療公司，但哪隻股票更好？我們將根據這兩家公司的估值、收益、盈利能力、分析師建議、風險、機構所有權和股息等方面的實力進行比較。
Profitability
盈利能力
This table compares Candel Therapeutics and Elevation Oncology's net margins, return on equity and return on assets.
此表比較了Candel Treeutics和Elevation Oncology的淨利潤率、股本回報率和資產回報率。
| Net Margins | Return on Equity | Return on Assets | |
| Candel Therapeutics | -29,132.26% | -18.07% | -11.94% |
| Elevation Oncology | N/A | -45.55% | -41.75% |
| 淨利潤率 | 股本回報率 | 資產回報率 | |
| 秋茄治療公司 | -29,132.26% | -18.07% | -11.94% |
| 高位腫瘤學 | 不適用 | -45.55% | -41.75% |
Earnings and Valuation
收益和估值
This table compares Candel Therapeutics and Elevation Oncology's top-line revenue, earnings per share and valuation.
此表比較了Candel Treeutics和Elevation Oncology的營收、每股收益和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Candel Therapeutics | $130,000.00 | 740.08 | -$36.12 million | ($0.81) | -4.11 |
| Elevation Oncology | N/A | N/A | -$32.04 million | ($2.54) | -0.42 |
| 總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
| 秋茄治療公司 | $130,000.00 | 740.08 | -3,612萬元 | ($0.81) | -4.11 |
| 高位腫瘤學 | 不適用 | 不適用 | -3,204萬元 | ($2.54) | -0.42 |
Insider & Institutional Ownership
內部人與機構所有權
22.0% of Candel Therapeutics shares are held by institutional investors. Comparatively, 74.0% of Elevation Oncology shares are held by institutional investors. 44.3% of Candel Therapeutics shares are held by company insiders. Comparatively, 17.0% of Elevation Oncology shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Candel治療公司22.0%的股份由機構投資者持有。相比之下，74.0%的Elevation Oncology股票由機構投資者持有。坎德爾治療公司44.3%的股份由公司內部人士持有。相比之下，Elevation Oncology 17.0%的股份由公司內部人士持有。強大的機構持股表明，捐贈基金、大型基金管理公司和對衝基金相信，一家公司的長期表現將好於大盤。
Analyst Ratings
分析師評級
This is a breakdown of current ratings for Candel Therapeutics and Elevation Oncology, as provided by MarketBeat.com.
這是由MarketBeat.com提供的Candel Treeutics和Elevation Oncology的當前評級細目。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Candel Therapeutics | 0 | 0 | 1 | 0 | 3.00 |
| Elevation Oncology | 0 | 1 | 3 | 0 | 2.75 |
| 銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
| 秋茄治療公司 | 0 | 0 | 1 | 0 | 3.00 |
| 高位腫瘤學 | 0 | 1 | 3 | 0 | 2.75 |
Candel Therapeutics currently has a consensus price target of $11.50, suggesting a potential upside of 245.35%. Elevation Oncology has a consensus price target of $7.75, suggesting a potential upside of 618.52%. Given Elevation Oncology's higher probable upside, analysts plainly believe Elevation Oncology is more favorable than Candel Therapeutics.
Candel治療公司目前的共識目標價為11.5美元，這意味着潛在的上漲245.35%。Elevation Oncology的共識目標價為7.75美元，暗示潛在上漲618.52。考慮到Elevation腫瘤學更有可能的上行空間，分析師們顯然認為Elevation腫瘤學比Candel治療更有利。
Volatility & Risk
波動性與風險
Candel Therapeutics has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500. Comparatively, Elevation Oncology has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500.
Candel Treateutics的貝塔係數為0.95，表明其股價的波動性比標準普爾500指數低5%。相比之下，Elevation Oncology的貝塔係數為0.82，表明其股價的波動性比標準普爾500指數低18%。
Summary
摘要
Candel Therapeutics beats Elevation Oncology on 7 of the 13 factors compared between the two stocks.
與兩隻股票相比，秋茄治療公司在13個因素中有7個超過了海拔腫瘤公司。
About Candel Therapeutics
關於秋茄治療公司
(Get Rating)
(獲取評級)
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.
Candel治療公司是一家臨牀階段的生物製藥公司，致力於為癌症患者開發免疫療法。該公司開發了CAN-2409，這是治療胰腺癌的第二階段臨牀試驗；治療前列腺癌的第三階段臨牀試驗；以及治療肺癌的第二階段臨牀試驗，以及治療高級別膠質瘤的Ib/II階段臨牀試驗。它還開發了CAN-3110，這是一種治療復發膠質母細胞瘤的I期臨牀試驗。該公司前身為Advantagene，Inc.，並於2020年11月更名為Candel治療公司。該公司成立於2003年，總部設在馬薩諸塞州的尼達姆。
About Elevation Oncology
關於立面腫瘤學
(Get Rating)
(獲取評級)
Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.
Elevation Oncology，Inc.是一家臨牀階段的生物製藥公司，專注於開發治療美國基因組定義的患者羣體中的癌症的療法。該公司的主導項目是Serbantumab，這是一種抗HER3的單抗，正處於Crestone第二階段試驗，用於治療含有neuRegin-1融合的晚期實體腫瘤。Elevation Oncology，Inc.成立於2019年，總部設在紐約。
Receive News & Ratings for Candel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Candel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《秋茄治療日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Candel Treateutics和相關公司的最新新聞和分析師評級的每日簡要摘要。